Adaptive immunity is a sophisticated and specialized defense mechanism within the immune system. It provides targeted, long-lasting protection against specific pathogens. The two primary components of adaptive immunity are T lymphocytes (T cells) and B lymphocytes (B cells). These cells undergo a process of maturation and differentiation, acquiring the ability to recognize and respond to specific antigens, which are molecular signatures of pathogens. B cells produce antibodies, proteins that can neutralize or eliminate pathogens. T cells, on the other hand, can directly attack infected cells and regulate immune responses. Adaptive immunity exhibits memory, allowing the immune system to "remember" previously encountered pathogens. This memory enables a faster and more robust response upon subsequent exposure, contributing to immune effectiveness. Immunization harnesses the principles of adaptive immunity by exposing the immune system to harmless components of pathogens, generating an immune memory without causing the disease. The remarkable specificity and versatility of adaptive immunity make it a crucial defense mechanism, protecting the body against a diverse array of pathogens and contributing to overall immune resilience.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States